Fritextsökning
Artiklar per år
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Hårt tryck på Läkemedelsverket
Alltför många vill ansöka om Sverige som referensland i den decentraliserade processen för att godkänna läkemedel. Idag införs nya rutiner för att hantera situationen.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Respiratorius hunts millions
The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
Pharma is a safe market
Pharma is the best industry to invest in. That states leaders from risk capital companies, interviewed by the Economist Intelligence Unit.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.